HIV News and Research

RSS

Longer reads: HIV secrets, millennials' mental health and sleeping pills without side effects

Every week reporter Ankita Rao selects interesting reading from around the Web.

6 Dec 2013

Mylan Pharmaceuticals introduces Cabergoline Tablets USP, 0.5 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

5 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

AAAS Honors Two Tufts University faculty members as Fellows

Two faculty members at Tufts University have been elected Fellows of the American Association for the Advancement of Science (AAAS), an honor bestowed upon AAAS members by their peers. John M. Coffin and planetary scientist Samuel P. Kounaves are among 388 new Fellows recognized by AAAS based on their distinguished efforts to advance science or its applications.

4 Dec 2013

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Antiretroviral therapy for the treatment of HIV infection has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030, according to a new study published online in The Journal of Infectious Diseases. The analysis suggests these dramatic benefits could be even greater if more aggressive HIV testing and treatment strategies are implemented.

4 Dec 2013

UCI-led study results have important implications for HIV vaccine development

Infectious disease researchers have identified a novel mechanism wherein HIV-1 may facilitate its own transmission by usurping the antibody response directed against itself. These results have important implications for HIV vaccine development and for understanding the earliest events in HIV transmission.

4 Dec 2013

Better understanding of cancer evolution could help in early detection of cancers

A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Older HIV-positive men at higher risk of HPV that causes anal cancer

Human papillomavirus, or HPV, which can cause cervical cancer in women, is also known to cause anal cancer in both women and men. Now, a study led by researchers at the UCLA School of Nursing has found that older HIV-positive men who have sex with men are at higher risk of becoming infected with the HPVs that most often cause anal cancer.

4 Dec 2013

AHF commends donors for rallying to pledge financial support for Global Fund

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, today heartily praised donor countries for rallying to pledge financial support for the Global Fund to Fight AIDS, TB, and Malaria.

4 Dec 2013

Virginia Mason a 2013 Top Hospital by The Leapfrog Group

Virginia Mason has been named a 2013 Top Hospital by The Leapfrog Group, making this the eighth consecutive year it has earned this national recognition.

3 Dec 2013

EU pledges over $500 million to fight AIDS, TB and malaria

The European Union today announced at the Global Fund's Replenishment Conference in Washington, DC, new support of over US $500 million to fight AIDS, tuberculosis and malaria for the 2014-2016 period. The conference takes place just one day after World AIDS Day.

3 Dec 2013

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

Viewpoints: Where's Obama's 'Mission Accomplished' banner?; health law critics overlooking those denied affordable care in the past

Great news: The White House says that Healthcare.gov and the 36 federally run insurance exchanges are finally good to go. The only thing missing from Sunday's relentlessly upbeat progress report was President Obama in front of a "Mission Accomplished" banner. Sunday's eight-page report was intended to meet Mr. Obama's deadline for fixing the site after its October 1 debut was a calamity. But the more important goal was political -- namely, claiming enough progress to prevent Democrats on Capitol Hill from joining the GOP demand for delaying the individual mandate to buy insurance or even the entire program (12/1).

3 Dec 2013

MiniVax wins $20,000 in NOBIC’s second annual BioChallenge business competition

MiniVax, Inc. (MiniVax) participated in the New Orleans BioInnovation Center's (NOBIC) second annual BioChallenge, a business competition part of the three-day Innovation Louisiana 2013 conference.

3 Dec 2013

U.S. Administration to provide $5 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria

In an address recognizing World AIDS Day, President Barack Obama announced today that the U.S. Administration will commit up to $5 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria over the next three years. Specifically, he said the United States will contribute $1 for every $2 provided by other donors worldwide through 2016, up to $5 billion.

3 Dec 2013

Virginia Mason first to use non-invasive FibroScan technology to evaluate liver diseases

Virginia Mason today becomes the first in the Pacific Northwest to use non-invasive FibroScan technology to evaluate disease stage in patients diagnosed with liver ailments.

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013